Cancer Family
Neoplasm
CI-CAN-00000001Explore in graph →
Non-malignant22,985 active trials259 approved drugs4,032 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000001Explore in graph →
Clinical trials
105,916 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05994339 | Radiotherapy Combined With Almonertinib for Stage III EGFR-Mutated Lung Cancer | unknown | Phase 2 / Phase 3 | 40 | Laibin People's HospitalOTHER | 0 | Aug 29, 2023 | clinicaltrials |
| NCT06015854 | Vvax001 Cancer Vaccine in Premalignant Cervical Lesions - Phase II(Vvax) | unknown | Phase 2 | 18 | University Medical Center GroningenOTHER | 1 | Aug 29, 2023 | clinicaltrials |
| NCT06016400 | Using Vitamin D to Reduce Oral Mucosal Inflammation in Chemotherapy Patients With Oral Squamous Cell Carcinoma | unknown | Phase 2 / Phase 3 | 412 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Aug 29, 2023 | clinicaltrials |
| NCT04309981 | Clinical Trial Using Humanized CART Directed Against BCMA (ARI0002h) in Patients With Relapsed/Refractory Multiple Myeloma to Proteasome Inhibitors, Immunomodulators and Anti-CD38 Antibody. | unknown | Phase 1 / Phase 2 | 73 | Sara V. LatorreOTHER | 1 | Aug 28, 2023 | clinicaltrials |
| NCT03808441 | CAcTUS - Circulating Tumour DNA Guided Switch(CAcTUS) | unknown | Phase 2 | 21 | The Christie NHS Foundation TrustOTHER | 1 | Aug 25, 2023 | clinicaltrials |
| NCT05869162 | Phase II Study of SY-3505 in Patients With ALK-positive NSCLC Who Have Failed Prior Second-Generation ALK TKI | unknown | Phase 2 | 153 | Shouyao Holdings (Beijing) Co. LTDOTHER | 1 | Aug 25, 2023 | clinicaltrials |
| NCT06010888 | Fruquintinib With mFOLFOX6/FOLFIRI as First-Line Therapy for Conversion Surgery in mCRC | unknown | Phase 2 | 92 | Fudan UniversityOTHER | 1 | Aug 25, 2023 | clinicaltrials |
| NCT06008925 | Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric Cancer | unknown | Phase 1 / Phase 2 | 43 | CNBG-Virogin Biotech (Shanghai) Ltd.INDUSTRY | 1 | Aug 24, 2023 | clinicaltrials |
| NCT06009848 | Cadonilimab Plus Nab-Paclitaxel for Recurrent or Metastatic Muscle Invasive Bladder Cancer | unknown | Phase 2 | 20 | Tianjin Medical University Second HospitalOTHER | 1 | Aug 24, 2023 | clinicaltrials |
| NCT06010212 | Fruquintinib as First Line Treatment in Patients With Recurrent Esophageal Squamous Cell Carcinoma | unknown | Phase 1 / Phase 2 | 36 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Aug 24, 2023 | clinicaltrials |
| NCT05892237 | CIETAI and Sequential Radiotherapy in Squamous Lung Cancer | unknown | Phase 2 | 50 | Dong WangOTHER | 1 | Aug 23, 2023 | clinicaltrials |
| NCT05957016 | Neoadjuvant CIETAI With Concurrent Chemoradiotherapy in Local Advanced Rectal Cancer | unknown | Phase 2 | 90 | Third Military Medical UniversityOTHER | 1 | Aug 23, 2023 | clinicaltrials |
| NCT06006104 | Phase 1/2 Clinical Study of HRS-4357 in Patients With Advanced Prostate Cancer | unknown | Phase 1 / Phase 2 | 49 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 0 | Aug 23, 2023 | clinicaltrials |
| NCT06003998 | Intraperitoneal Irinotecan With Concomitant FOLFOX and Bevacizumab(INTERACT-II) | unknown | Phase 2 | 85 | Catharina Ziekenhuis EindhovenOTHER | 1 | Aug 22, 2023 | clinicaltrials |
| NCT02471391 | ABT-199 & Ibrutinib in Mantle Cell Lymphoma (AIM)(AIM) | unknown | Phase 2 | 37 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Aug 21, 2023 | clinicaltrials |
| NCT03331731 | A Phase II Study to Determine Pembrolizumab as Frontline Treatment of Patients With Hodgkin Lymphoma(PLIMATH) | unknown | Phase 2 | 27 | Peter MacCallum Cancer Centre, AustraliaOTHER | 2 | Aug 21, 2023 | clinicaltrials |
| NCT04984369 | The Efficacy of HLX208 (BRAF V600E Inhibitor) With Cetuximab for Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation After First-line Treatment | unknown | Phase 2 | 50 | Shanghai Henlius BiotechINDUSTRY | 1 | Aug 21, 2023 | clinicaltrials |
| NCT05102292 | The Efficacy and Safety of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 Mutation | unknown | Phase 1 / Phase 2 | 25 | Shanghai Henlius BiotechINDUSTRY | 1 | Aug 21, 2023 | clinicaltrials |
| NCT05996484 | Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma | unknown | Phase 2 | 25 | Nanfang Hospital, Southern Medical UniversityOTHER | 0 | Aug 21, 2023 | clinicaltrials |
| NCT06000033 | Study of Disitamab Vedotin and Anlotinib in Patients With HR-Negative, HER2-Low-Expressing Metastatic Breast Cancer | unknown | Phase 2 | 35 | Qilu Hospital of Shandong UniversityOTHER | 0 | Aug 21, 2023 | clinicaltrials |
| NCT04659382 | Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer(SIRTCI) | unknown | Phase 2 | 52 | Federation Francophone de Cancerologie DigestiveOTHER | 1 | Aug 18, 2023 | clinicaltrials |
| NCT04798612 | Effect of Low-dose Interferon-alfa2a on Peri-operative Immune Suppression(IPOS) | unknown | Phase 2 | 68 | Zealand University HospitalOTHER | 1 | Aug 18, 2023 | clinicaltrials |
| NCT05997459 | A Single Arm, Phase II Exploratory Clinical Study of Pemitinib in Advanced Gastric Cancer With Previous Standard Therapy Failure the FGFR Variant | unknown | Phase 2 | 23 | Sun Yat-sen UniversityOTHER | 1 | Aug 18, 2023 | clinicaltrials |
| NCT03215693 | X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib | unknown | Phase 2 | 152 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Aug 16, 2023 | clinicaltrials |
| NCT05994456 | Neoadjuvant Toripalimab for dMMR/MSI-H Gastric Cancer | unknown | Phase 2 | 24 | Sun Yat-sen UniversityOTHER | 1 | Aug 16, 2023 | clinicaltrials |
| NCT04135690 | HAIC Plus Toripalimab vs. HAIC Plus Sorafenib for HCC With PVTT: a Non-comparative, Prospective, Randomized Trial | unknown | Phase 2 | 60 | Sun Yat-sen UniversityOTHER | 1 | Aug 15, 2023 | clinicaltrials |
| NCT05023109 | GP Chemotherapy in Combination With Anti-PD-1 and Anti-TIGIT in Unresectable Advanced BTC | unknown | Phase 2 | 45 | Shanghai Zhongshan HospitalOTHER | 1 | Aug 15, 2023 | clinicaltrials |
| NCT05156788 | Tislelizumab（Anti PD-1), Lenvatinib and GEMOX Transformation in the Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer | unknown | Phase 2 | 40 | Shanghai Zhongshan HospitalOTHER | 1 | Aug 15, 2023 | clinicaltrials |
| NCT03961698 | Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma(MARIO-3) | unknown | Phase 2 | 91 | Infinity Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 14, 2023 | clinicaltrials |
| NCT05986981 | MUC1 Therapeutic Tumor Vaccine in Advanced Solid Cancers | unknown | Phase 2 | 20 | Peking Union Medical College HospitalOTHER | 1 | Aug 14, 2023 | clinicaltrials |
| NCT04156698 | Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma | unknown | Phase 2 | 51 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Aug 9, 2023 | clinicaltrials |
| NCT05235906 | A Phase II Clinical Study of Surufatinib Combined With Sintilimab in the Treatment of Advanced Gastric Cancer | unknown | Phase 2 | 61 | Sun Yat-sen UniversityOTHER | 1 | Aug 9, 2023 | clinicaltrials |
| NCT05982834 | Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC | unknown | Phase 1 / Phase 2 | 43 | Fudan UniversityOTHER | 1 | Aug 9, 2023 | clinicaltrials |
| NCT04297995 | Evaluate the Efficacy and Safety of HLX10 in Combination With HLX07 in Patients With Advanced Head and Neck Tumors | unknown | Phase 2 | 131 | Shanghai Henlius BiotechINDUSTRY | 1 | Aug 8, 2023 | clinicaltrials |
| NCT05102214 | HLX301 (TIGIT×PDL1 Bispecific) in Patients With Locally Advanced or Metastatic Solid Tumors | unknown | Phase 1 / Phase 2 | 150 | Shanghai Henlius BiotechINDUSTRY | 1 | Aug 8, 2023 | clinicaltrials |
| NCT05127759 | The Efficacy and Safety of HLX208 in Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation | unknown | Phase 2 | 25 | Shanghai Henlius BiotechINDUSTRY | 1 | Aug 8, 2023 | clinicaltrials |
| NCT05390528 | A Study Evaluating the Safety, Tolerability, Pharmacokinetic and Efficacy of HLX301(TIGIT×PDL1 Bispecific) in Locally Advanced/Metastatic Solid Tumors or Lymphoma(HLX301) | unknown | Phase 1 / Phase 2 | 30 | Shanghai Henlius BiotechINDUSTRY | 1 | Aug 8, 2023 | clinicaltrials |
| NCT05840835 | Study of IMX-110 in Combination With Tislelizumab in Patients With Advanced Solid Tumors(IMMINENT-01) | unknown | Phase 1 / Phase 2 | 60 | Immix Biopharma, Inc.INDUSTRY | 1 | Aug 8, 2023 | clinicaltrials |
| NCT05981157 | Anrotinib and Tirelizumab in First-line Treatment of RM-NPC | unknown | Phase 2 | 27 | Zhongshan People's Hospital, Guangdong, ChinaOTHER | 1 | Aug 8, 2023 | clinicaltrials |
| NCT05982301 | Sintilimab Combined With Modified FLOT Regimen in the Treatment of Metastatic Gastric Cancer | unknown | Phase 2 | 87 | Fudan UniversityOTHER | 1 | Aug 8, 2023 | clinicaltrials |
| NCT03363867 | BEACON - ABC in Recurrent Platinum Resistant HGSOC(BEACON) | unknown | Phase 2 | 30 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Aug 7, 2023 | clinicaltrials |
| NCT05900973 | A Phase 2 Trial of Darolutamide as a Prostate-Specific Membrane Antigen (PSMA) Expression Enhancer in Patients With Localized Prostate Cancer | unknown | Phase 2 | 19 | D'Or Institute for Research and EducationOTHER | 1 | Aug 7, 2023 | clinicaltrials |
| NCT05978401 | Safety, Tolerability, and Efficacy of GLS-012 and GLS-010 in Patients With Advanced Non-Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 152 | Guangzhou Gloria Biosciences Co., Ltd.INDUSTRY | 1 | Aug 7, 2023 | clinicaltrials |
| NCT03867682 | Venetoclax and Lintuzumab-Ac225 in AML Patients | unknown | Phase 1 / Phase 2 | 38 | Actinium PharmaceuticalsINDUSTRY | 1 | Aug 4, 2023 | clinicaltrials |
| NCT05975944 | Study of Selinexor Combined With Olaparib in Relapsed/Refractory Extensive Stage Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 49 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 4, 2023 | clinicaltrials |
| NCT05974059 | Cadonilimab Combined With CapeOX Regimen in Perioperative Treatment of Resectable Locally Advanced Gastric Cancer | unknown | Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT05974085 | XPO-1 in Combination With RCHOP for DH/TH Lymphoma | unknown | Phase 2 | 10 | Zhejiang Cancer HospitalOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT05971199 | Phase II Study of Fruquintinib Combined With Sintilimab and TACE for Inoperable Primary Hepatocellular Carcinoma | unknown | Phase 2 | 27 | Zhejiang Cancer HospitalOTHER | 1 | Aug 2, 2023 | clinicaltrials |
| NCT04250948 | Efficacy of Perioperative Chemotherapy Plus PD-1 Antibody in the Locally Advanced Gastric Cancer | unknown | Phase 2 | 108 | Sun Yat-sen UniversityOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05266196 | A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577) | unknown | Phase 1 / Phase 2 | 10 | Salarius Pharmaceuticals, LLCINDUSTRY | 1 | Aug 1, 2023 | clinicaltrials |
Data updated 24 days agoSource updated Aug 29, 2023source: clinicaltrials